SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report: September 16, 1998
MEDIMMUNE, INC.
(Exact name of registrant as specified in its charter)
Commission File Number: 0-19131
Delaware 52-1555759
(State of Incorporation) (I.R.S. Employer
Identification No.)
35 West Watkins Mill Road, Gaithersburg, MD 20878
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (301) 417-0770
No Exhibits are being filed with this report
CytoGam and RespiGam are registered trademarks of the Company and Synagis is a
trademark.
MEDIMMUNE, INC.
Current Report on Form 8-K
ITEM 5. OTHER EVENTS
MedImmune, Inc. reported the information contained in the following press
release dated September 15, 1998:
MEDIMMUNE APPOINTS MELVIN BOOTH PRESIDENT & CHIEF OPERATING OFFICER
- Management Responsibilities Aligned to Focus on Next Phase of Growth -
Gaithersburg, MD, September 15, 1998 -- MedImmune (Nasdaq:MEDI) today announced
that Melvin D. Booth has joined the Company as President and Chief Operating
Officer and is expected to be elected to the Board of Directors at the next
meeting. Mr. Booth will report to Wayne T. Hockmeyer, Ph.D., Chairman and Chief
Executive Officer, and be responsible for all the operating functions of the
Company including, Marketing & Sales, Manufacturing, Engineering and Facilities,
Regulatory and Human Resources. Mr. Booth was most recently President and Chief
Operating Officer of Human Genome Sciences, Inc. (Nasdaq:HGSI) and prior to that
served for twenty years at Syntex Corporation, including as President of Syntex
Laboratories, the U.S. pharmaceutical operating unit of Syntex Corporation.
"As MedImmune enters an exciting new phase of growth with the launch of our new
product Synagis, I am delighted to have Mel join the management team. His
talent, experience and leadership skills in building and running large
pharmaceutical company operations at Syntex and now more recently in building a
successful biotechnology business at Human Genome Sciences will be real
strengths for us," commented Wayne T. Hockmeyer, Ph.D., Chairman and Chief
Executive Officer.
David Mott, formerly President and Chief Operating Officer, now Vice Chairman
and Chief Financial Officer will continue to report to Dr. Hockmeyer. Mr.
Mott's direct responsibilities will include Finance, Business Development and
Strategic Planning. Dr. Hockmeyer will have direct responsibility for Research,
Development and Clinical Affairs.
Dr. Hockmeyer added that, "Mel's years of operating experience significantly
strengthens the current management team at MedImmune and positions us well to
focus most effectively on the three critical areas for MedImmune's future
growth: product development, commercialization and strategic initiatives. I
believe MedImmune is at the early stages of a long-term growth cycle. Mel's
presence should increase our opportunities to successfully grow and build the
business and ensure continued excellence in operations, while carefully
evaluating new opportunities to expand the business."
While at Human Genome Sciences, Mr. Booth was involved in growing the business
into a leading genomic research and development company with the goal of
building a fully integrated pharmaceutical company. During his tenure, Human
Genome grew from 180 employees to approximately 400 employees and the company
now has what it believes is the most complete set of human genes, including two
product candidates currently in the clinic. Prior to joining Human Genome
Sciences in 1995, Mr. Booth served in various executive capacities at Syntex,
including as President of the U.S. pharmaceutical business, Syntex Laboratories.
Previously, Mr. Booth served as President of Syntex Pharmaceuticals Pacific,
President of Syntex Canada and President of Syntex Dental Products, Inc.
"Mel brings us the experience of an executive who has successfully run a
pharmaceutical business with over $1 billion in annual sales, and who has also
shown the ability to excel in the entrepreneurial biotechnology environment,"
added David Mott, Vice Chairman and Chief Financial Officer. "I believe that
the addition of Mr. Booth to our management team will enhance our ability to
assure continued excellence in all areas of the business as the Company's growth
accelerates over the next several years. Mel's extensive experience and
contacts within the pharmaceutical industry will also provide MedImmune with
valuable new insight and opportunities for future growth as we now seek to build
on the base we have established over MedImmune's first ten years."
MedImmune is a biotechnology company focused on developing and marketing
products for the prevention and treatment of infectious diseases and for use in
transplantation medicine. MedImmune markets three products through its hospital-
based sales force and has four new product candidates in clinical trials.
MedImmune is located in Gaithersburg, MD.
This announcement contains, in addition to historical information, certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions. Actual
results could differ materially from those currently anticipated as a result of
a number of factors, including risks and uncertainties discussed in the
Company's filings with the U.S. Securities and Exchange Commission.
(REGISTRANT) MEDIMMUNE, INC.
BY (SIGNATURE) /s/ David M. Mott
(NAME AND TITLE) David M. Mott, Vice Chairman and Chief Financial Officer
(DATE) September 16, 1998
